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Introduction
It is estimated that more than 40% of patients with
type 2 diabetes mellitus (T2DM) worldwide use pre-
mixed insulin as part of their therapeutic regimen
(1). Premixed insulin usually contains a rapid-acting
insulin and an intermediate-acting insulin to mimic
endogenous insulin secretion patterns and should be
taken twice daily, normally before breakfast and din-
ner (2). While the newer premixed insulin analogues
may confer greater improvements in glycaemic
control compared with regular human insulin or
neutral protamine Hagedorn (NPH) insulin (3), for
many patients, premixed insulin alone is insufﬁcient
to maintain adequate glycaemic control and is associ-
ated with signiﬁcant day-to-day variability (2).
Optimising fasting blood glucose (FBG) with pre-
mixed insulin may, therefore, increase the risk of
hypoglycaemia and may not provide sufﬁcient ﬂexi-
bility for patients to achieve optimal glycaemic con-
trol (4). The LAPTOP study has demonstrated that,
for insulin-naı ¨ve patients, a regimen composed of
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SUMMARY
Aim: Premixed insulin regimens are commonly used for type 2 diabetes mellitus
(T2DM) patients. However, there is limited information regarding next-step therapy
options in cases where premixed insulin does not provide adequate glycaemic con-
trol. This 12-week observational study of everyday clinical practice evaluated the
efﬁcacy and safety of insulin glargine (glargine) plus oral antidiabetic drugs (OADs)
in T2DM patients previously treated with premixed insulin. Methods: Type 2 dia-
betes mellitus patients taking premixed insulin were identiﬁed from German clinics
and were eligible to switch to glargine plus OADs at the physicians’ and patients’
discretion, as part of routine clinical practice. The study design and conduct was in
accordance with German regulations. Fasting blood glucose (FBG), 2-h postprandial
blood glucose (PPBG) and glycosylated haemoglobin (HbA1c) were measured at the
start and after a 12-week observation period. Results: A total of 5045 patients
were followed-up and received glargine plus OADs. FBG [start to end-point:
9.9 ± 2.7 to 6.9 ± 1.5 mmol/l (178 ± 48 to 124 ± 26 mg/dl); p £ 0.001], 2-h
PPBG [10.8 ± 2.8 to 7.8 ± 1.5 mmol/l (195 ± 50 to 140 ± 27 mg/dl)] and HbA1c
(8.3 ± 1.2 to 7.2 ± 0.8%; p £ 0.001) improved signiﬁcantly from start to end-
point, respectively. A total of 48.9%, 38.4% and 73.9% of patients had FBG
< 6.7 mmol/l (< 120 mg/dl), 2-h PPBG < 7.2 mmol/l (< 130 mg/dl) or HbA1c
< 7.5%, respectively, after 12 weeks. Signiﬁcant reductions in body weight were
observed between the start and end of the observation period. A total of 71
adverse events were reported by 38 patients. Hypoglycaemia was the most com-
mon event (n ¼ 16). Conclusions: This observational study shows that, in T2DM
patients inadequately controlled with premixed insulin, switching therapy to glar-
gine plus OADs is associated with signiﬁcant improvements in FBG and HbA1c, and
is well tolerated in everyday clinical practice. Further intensiﬁcation of insulin
therapy, perhaps by adding one or more injections of prandial insulin, would help
provide further improvements in glycaemic control in these patients.
What’s known
Pharmacological therapy of type 2 diabetes mellitus
typically starts with oral agents, including
metformin or sulfonylurea. However, the natural
progression of type 2 diabetes mellitus means that
combination therapy is often required. One option
to starting insulin therapy is the addition of a
‘basal’ insulin to help manage fasting blood
glucose.
What’s new
Premixed insulin is used by approximately 40% of
patients with type 2 diabetes mellitus, but for many
people, premixed insulin provides inadequate
glycaemic control. In this observational study of
everyday clinical practice, transferring from
premixed insulin to insulin glargine was associated
with signiﬁcant improvements in HbA1c and fasting
blood glucose. Thus, the switch to insulin glargine
offers an alternative treatment option for patients
with inadequate glycaemic control on premixed
insulin.
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 ; sanoﬁ-
aventis, Frankfurt, Germany) plus oral antidiabetic
drugs (OADs) is associated with better glycaemic
control and reduced risk of hypoglycaemia compared
with premixed insulin (4). Despite this, there is
limited information regarding therapeutic options
for patients for whom premixed insulin provides
inadequate glycaemic control or whom frequently
experience episodes of hypoglycaemia.
The aim of this observational study was to evalu-
ate the efﬁcacy and safety of insulin glargine with
concomitant OADs in everyday clinical practice when
used by patients with T2DM who were previously
treated with premixed insulin.
Methods
Study design
This 12-week study was an open-label, non-interven-
tional, multicentre (n ¼ 1791), observational study
of patients with T2DM in Germany and based in
everyday clinical practice.
This type of study is regulated by the German
Drug Law [Arzneimittelgesetz (AMG)] section 67 (6)
and is primarily intended to gather knowledge about
the safety and efﬁcacy of marketed drugs in daily
practice. As part of the sponsor’s obligations, the
National Association of Statutory Health Insurance
Physicians (Kassena ¨rztliche Bundersvereinigungen)
was notiﬁed of the implementation of this observa-
tional study. Owing to the non-interventional nature
of this observational study, no ethical approval or
informed patient consent was obtained, in accor-
dance with local regulations (AMG), and participa-
tion was voluntary. Participating general
practitioners (GPs) were asked to document their
everyday experience in treating patients with insulin
glargine in combination with OADs and received a
small compensation for the documentation of each
patient, which is common practice for this type of
study. All changes in therapy, which were recorded
as part of this observational study, were at the discre-
tion of the physician and the patient.
Patients and study conduct
Patients with T2DM and who were treated with reg-
ular human or analogue premixed insulin (most fre-
quently prescribed ratios: 25/75 and 30/70) with or
without OADs, were eligible for inclusion in this
observational study of everyday clinical practice. The
decision to use a therapy regimen including insulin
glargine with or without OADs was at the discretion
of the physicians and patients, and depended mainly
on subjective parameters, as reported by the physi-
cian, including: lack of efﬁcacy of premixed insulin,
patient wanting a more ﬂexible lifestyle, ability to
give up between-meal snacks, frequent occurrence of
hypoglycaemia with previous therapy, insufﬁcient
mixtures of insulin suspensions available and lack of
tolerability with previous therapy. Exclusion criteria
were according to the indications and contra-indica-
tions (i.e. patients hypersensitive to insulin glargine
or any of the excipients) given in the prescribing
information and summary of product characteristics
for insulin glargine.
At the start of the observation, patients were given
insulin glargine to be administered once daily via
subcutaneous injection; dosing decisions were at the
discretion of the physician, although, when switching
from twice-daily NPH insulin, a reduction in the
daily dose of insulin by 20–30% is recommended,
followed by adjustment of the daily dose (5). Con-
comitant OAD therapy (dosage, type and changes
where necessary) was at the discretion of the physi-
cian. All patients in the insulin glargine + OAD set
received OADs during the observational study. After
the initial visit (week 0; start of observation), subse-
quent visits were scheduled at weeks 2, 6 and 12
(end of observation).
The case report form speciﬁed that up to a maxi-
mum of nine blood glucose (BG) values [FBG, 1-h
postprandial blood glucose (PPBG) and 2-h PPBG
morning, mid-day and evening] should be docu-
mented at the start of the observation period and at
each follow-up examination. Self-monitored blood
glucose (SMBG) was performed using the patients’
own BG meter. Physicians gave all patients training
to ensure they could perform SMBG correctly and
accurately. Optimum titration of the insulin dose
was to the target FBG value of £ 5.5 mmol/l
(£ 100 mg/dl) and was measured by the subject via
SMBG. An FBG in the range of 5.0–6.7 mmol/l
(90–120 mg/dl) and 2-h PPBG in the range of
7.2–8.9 mmol/l (130–160 mg/dl) were considered clin-
ically important to show improvements in glycaemic
control with insulin glargine after 12 weeks therapy.
Glycosylated haemoglobin (HbA1c) measurements
were made at the start and at the end of the observa-
tional period using HbA1c measurement systems that
were aligned with the original Diabetes Control and
Complications Trial method (AlcNow
TM, Metrika
Inc., Sunnyvale, CA, USA or DCA
ª 2000+ analyzer,
Bayer Diagnostics, Eckhart, IN, USA). Owing to the
relatively short duration of the observation period,
the therapeutic target at week 12 for HbA1c was set
at < 7.5%, which was considered clinically important
to show improvements in glycaemic control with
insulin glargine.
Adverse events (AEs), which included episodes of
hypoglycaemia, and adverse drug reactions (ADRs)
Re-use of this article is
permitted in accordance with
the Creative Commons Deed,
Attribution 2.5, which does not
permit commercial exploitation.
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as and when they occurred. All events were recorded
by the physician. Patients and physicians were not
requested to provide details of episodes of hypoglyca-
emia, such as symptomatic/non-symptomatic or
BG levels.
At the end of the observation period, physicians
were asked to complete a 5-item questionnaire to
investigate how they rated aspects of therapy with
insulin glargine (BG control, safety, weight manage-
ment, patients’ quality of life and demand on physi-
cian time). Each item was rated as very good, good,
satisfactory or unsatisfactory. Physicians were also
asked to note whether therapy with insulin glargine
was to be continued. If therapy with insulin glar-
gine was to be discontinued, reasons for discontinua-
tion were to be given.
Data validation
Dual data entry was performed for some variables
(case report form number, patient number, sex and
date of birth) to ensure correct identiﬁcation of
patients and prevent duplicate patient entry. Valida-
tion methods were used to ensure all data were
within plausible ranges (any extreme values were fol-
lowed up) and in the correct order (e.g. the date
listed for the ﬁrst visit was earlier than the date listed
for the last visit; incorrect dates were corrected using
the original case report form).
Population subsets and statistical analysis
All patients who met the inclusion/exclusion criteria
were included in the full data set. Five analysis sets
were identiﬁed for the purpose of this observational
study:
• Total population: all patients who were enrolled in
this observational study.
• Full data set: patients with T2DM who were previ-
ously treated with premixed insulin, with or without
OADs prior to the start of observation. Patients in
the full data set were treated with insulin glargine
with or without OADs during the observation period.
• Prior premixed insulin – OAD set: all patients
who were treated with premixed insulin without
OADs prior to the observational study. Patients in
the prior premixed insulin – OAD group were trea-
ted with or without OADs during the observation
period.
• Prior premixed insulin + OAD set: all patients
who were treated with premixed insulin with OADs
prior to the observational study. Patients in the prior
premixed insulin + OAD group were treated with or
without OADs during the observation period.
• Insulin glargine + OAD set: all patients who were
treated with insulin glargine plus OADs during the
observational period. Prior to the study, patients in
the insulin glargine + OAD set were treated with
premixed insulin with or without OADs.
Descriptive statistics are presented. The Wilcoxon
signed rank test was used to evaluate changes in
FBG, HbA1c and body weight between the start and
end of observation. Data are presented as means with
standard deviation. Statistical analyses were per-
formed using SPSS for Windows (version 11.01;
SPSS Inc., Chicago, IL).
Results
Population characteristics at the start
of observation
The ofﬁcial start of the observation period was
February 2004 and the last available follow up was
December 2004. A total of 6560 patients from 1791
centres (general medicine, 56.0%; internal medicine,
27.9%; GP, 13.9%; other/no data available, 2.2%) were
included in the analysis of this surveillance study with
insulin glargine (safety analysis set). A total of 49.7%
were male and 49.7% were female (no data were avail-
able for 0.6% of the patients). Median age was 63.2
and 66.3 years, and median body mass index (BMI)
was 28.4 and 29.0 kg/m
2 for males and females, respec-
tively. Characteristics of the subsets of patients at the
start of observation are summarised in Table 1.
Of the 6560 patients that comprised the full data
set, 252 patients did not meet the criteria for data
analysis (for 244 patients, the previous therapy was
not premixed insulin; two patients did not have
T2DM; six patients did not meet either criterion).
The remaining 6308 T2DM patients were switched
from premixed insulin to insulin glargine as part of
their clinical management. These patients, thus, com-
prised the full data set. Of these, a total of 3098
patients were treated with premixed insulin without
OADs (prior premixed insulin – OADs) and 3210
patients were treated with premixed insulin plus
OADs (prior premixed insulin + OADs), prior to the
start of the observation period. A total of 5045
patients were treated with premixed insulin (with or
without OADs) prior to the start of the observation
period and switched therapy to insulin glargine plus
OADs (insulin glargine + OAD set).
At the start of observation, a total of 62.6% of
patients in the full data set had experienced one, or
more, secondary complications associated with diabe-
tes (Table 1); 45.5%, 34.5%, 22.9% and 6.6% had
microalbuminuria, neuropathy, retinopathy or mac-
roalbuminuria, respectively.
In the full data set, the most common reasons
given by physicians and patients for switching from
premixed insulin to insulin glargine included: lack
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wanting a more ﬂexible lifestyle (55.6%), ability to
give up between meal snacks (37.1%) and frequent
occurrence of hypoglycaemia with previous therapy
(23.5%). Of those citing frequent occurrence of
hypoglycaemia (n ¼ 1306), the mean number of
episodes per person in the 3 months preceding the
observation period was 5.0 ± 4.2 (median: 4.0).
Less frequent reasons cited for switching from pre-
mixed insulin to insulin glargine included insufﬁ-
cient mixtures of insulin suspensions available
(13.7%) and lack of tolerability with previous ther-
apy (13.3%).
Efﬁcacy
Glycaemic control improved signiﬁcantly in patients
within each subset, with signiﬁcant improvements in
FBG (Figure 1A) and HbA1c (Figure 1B).
In the full data set, the mean decrease in FBG
was 3.0 ± 2.6 mmol/l (54.7 ± 46.3 mg/dl) and the
median decrease was 2.7 mmol/l [48 mg/dl; inter-
quartile range: )4.2 to )1.5 mmol/l ()75.0 to
)27.0 mg/dl)]. As a result, of those patients who
provided FBG measurements at the end of the
observation (5998 of 6308), 2643 (44.1%) met
the therapeutic target for FBG [5.0–6.7 mmol/l
Table 1 Characteristics of patients who were included in this observational study
Factor
Full data set
(n ¼ 6308)
Prior premixed
insulin – OADs
(n ¼ 3098)
Prior premixed
insulin + OADs
(n ¼ 3210)
Insulin
glargine + OAD
set (n ¼ 5045)
n % n % n % n %
Duration of diabetes (years)* 5144 (8.6 ± 6.1) 2497 (8.6 ± 6.3) 2647 (8.7 ± 6.0) 4143 (8.7 ± 5.9)
Secondary disorders
Patients with disorders 3950 62.6 1890 61.0 2060 64.2 3191 63.3
Micro-albuminuria 2871 45.5 1383 44.6 1488 46.4 2317 45.9
Macro-albuminuria 419 6.6 221 7.1 198 6.2 333 6.6
Retinopathy 1442 22.9 665 21.5 777 24.2 1160 23.0
Neuropathy 2174 34.5 1041 33.6 1133 35.3 1767 35.0
Prior insulin therapy
10/90 only 26 0.4 9 0.3 17 0.5 20 0.4
15/85 only 30 0.5 13 0.4 17 0.5 20 0.4
20/80 only 141 2.2 74 2.4 67 2.1 102 2.0
25/75 only 1167 18.5 579 18.7 588 18.3 961 19.1
30/70 only 4381 69.5 2132 68.8 2249 70.1 3509 69.6
40/60 only 72 1.1 35 1.1 37 1.2 45 0.9
50/50 only 315 5.0 163 5.3 152 4.7 250 5.0
Other 34 0.5 11 0.4 23 0.7 27 0.5
More than one formulation 142 2.3 82 2.7 60 1.9 111 2.2
Insulin dose*,,,§
25/75 (U/day) 1193 (35.3 ± 15.5) 595 (36.6 ± 14.9) 598 (33.9 ± 16.0) 978 (35.4 ± 15.5)
30/70 (U/day) 4317 (35.2 ± 14.8) 2109 (35.8 ± 14.9) 2208 (34.6 ± 14.6) 3464 (35.3 ± 14.7)
Prior OAD therapy
Patients taking OADs 3210 50.9 n/a n/a 3210 100.0 3080 61.1
Glimepiride 847 13.4 n/a n/a 847 26.4 811 16.1
Glibenclamide 593 9.4 n/a n/a 593 18.5 559 11.1
Metformin 2192 34.8 n/a n/a 2192 68.3 2117 42.0
Other OAD– 160 2.5 n/a n/a 160 5.0 155 3.1
Concomitant OAD therapy
Patients taking OADs 5045 80.0 1965 63.4 3080 96.0 5045 100.0
As some patients had incomplete data, the numbers of patients with valid data for each characteristic are given. Reasons for missing data were not collected.
Results are n and per cent except *mean ± SD. Patients can be in more than one subcategory. Premixed insulin formulation previously used (soluble/protaminated
insulin). §Mean daily dose of premixed insulin prior to the start of the observation period. –Includes acarbose (full data set, n ¼ 61), repaglinide (34), pioglitazone
(21), nateglinide (17), rosiglitazone (13) or another OAD (17). Full data set ¼ all patients who fulﬁlled the inclusion criteria; prior premixed insulin – OAD ¼ all
patients who were treated with premixed insulin without OADs prior to the observational study; prior premixed insulin + OAD ¼ all patients who were treated with
premixed insulin plus OADs prior to the observational study. Insulin glargine + OAD set ¼ all patients who were treated with insulin glargine plus OADs during the
observational period. OADs, oral antidiabetic agents.
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had FBG < 5.0 mmol/l (< 90 mg/dl) (Table 2). The
mean decrease in HbA1c was 1.1 ± 1.0%, with a
median of )1.0% (interquartile range: )1.50 to
)0.50%). Thus, of 6179 (of 6308) patients for
whom HbA1c was measured at the end of the
observation, 4593 (74.3%) had HbA1c < 7.5%
(Table 2).
(A)
(B)
Figure 1 Fasting blood glucose (FBG; A) and glycosylated haemoglobin (HbA1c; B) at the start (open bars) and end
(closed bars) of the 12-week observation period in the full data set (n ¼ 6308; all patients who fulﬁlled the inclusion
criteria), the prior premixed insulin – oral antidiabetic drugs (OADs) set (n ¼ 3098; all patients who were treated with
premixed insulin without OADs prior to the observational study), the prior premixed insulin + OAD set (n ¼ 3210; all
patients who were treated with premixed insulin plus OADs prior to the observational study) and the insulin
glargine + OAD set (n ¼ 5045; all patients who were treated with insulin glargine plus OADs during the observational
period). *p £ 0.001 for the within-group change in FBG or HbA1c from the start to the end of the observation period
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tions of patients who achieved the target FBG or
HbA1c were similar in each of the subsets, including
the insulin glargine + OAD set.
In the full data set, reductions in both fasting pre-
prandial BG and 2-h PPBG levels were observed over
the 12-week observation period (Table 3) and the
majority of patients reached target 2-h PPBG levels
of 7.2–8.9 mmol/l (130–160 mg/dl) (Table 3). Simi-
lar reductions in both fasting preprandial and PPBG
levels were observed in patients who were treated
with premixed insulin + OADs or premixed insulin
– OADs prior to the observation period (Table 3). In
the insulin glargine + OAD set, fasting preprandial
and 2-h PPBG levels decreased by 2.9 mmol/l
(52 mg/dl) and 3.1 mmol/l (55 mg/dl), respectively
(Table 3). A total of 81.6% of patients in the insulin
glargine + OAD set achieved the target 2-h PPBG
level of 7.2–8.9 mmol/l (130–160 mg/dl).
Body weight
In the full data set, signiﬁcant reductions in body
weight were observed between the start and end of the
observation period ()1.5 ± 3.3 kg; p £ 0.001; median
change in body weight: )1.0 kg; interquartile range:
)3 to 0 kg) (Table 3). Reductions in body weight
were of a similar magnitude and were statistically sig-
niﬁcant in the other subsets of the study population.
Insulin dose and oral antidiabetic therapy
In the full data set, the mean daily dose of insulin
increased by 4 U between week 0 (22.1 ± 10.6 U)
and week 12 (26.3 ± 11.6 U). A similarly low
increase in the daily insulin dose was seen in
patients in the other subsets of the total popula-
tion.
In the insulin glargine + OAD group, there were
no changes in the frequency of patients taking each
OAD between the start and end of the observation;
metformin (54.8% vs. 58.2% for start vs. end of
observation) glimepiride (40.5% vs. 44.5%) and gli-
benclamide (10.9% vs. 9.8%) were used most fre-
quently. The proportion of patients taking other
OADs was 4.4% and 5.2% at the start and end of
observation, respectively.
Safety
All patients (n ¼ 6560) were included in the full data
set. A total of 71 AEs were reported in 38 patients;
of these, 33 events (17 patients) were classed as seri-
ous AEs. Hypoglycaemia was the most commonly
reported AE (16 events), followed by hyperhydrosis
(three events).
A total of 30 events in 14 patients were classed
as ADRs; hypoglycaemia was the most commonly
reported ADR (13 events), followed by hyperhyd-
rosis (three events), over the 12-week observation
period. Two patients died during the course of
the observation period; one was due to acute kid-
ney failure, which was not considered related to
the treatment regimen, but no indication was
available for the second, thus it was not possible
to determine whether it was related to treatment
or not.
Table 2 Proportion of patients who achieved clinically relevant fasting blood glucose levels [5.0–6.7 mmol/l (90–120 mg/dl)] or HbA1c (< 7.5%)
at week 12
Full data set
(n ¼ 6308)
Prior premixed
insulin – OADs
(n ¼ 3098)
Prior premixed
insulin + OADs
(n ¼ 3210)
Insulin
glargine + OAD
set (n ¼ 5045)
n % n % n % n %
FBG
Number of patients with FBG measurement 5998 2930 3068 4815
< 5.0 mmol/l (< 90 mg/dl) 272 4.5 128 4.4 144 4.7 214 4.4
5.0–6.7 mmol/l (90–120 mg/dl) 2643 44.1 1335 45.6 1308 42.6 2139 44.4
Total < 6.7 mmol/l (< 120 mg/dl) 2915 48.6 1463 49.9 1452 47.3 2353 48.9
HbA1c
Number of patients with HbA1c measurement 6179 3033 3146 4965
< 7.5% 4593 74.3 2277 75.1 2316 73.6 3670 73.9
As some patients had incomplete data, the number of patients with valid data for each characteristic are given. Results are n and per cent of patients who provided
valid data for that characteristic. Reasons for missing data were not collected. Full data set ¼ all patients who fulﬁlled the inclusion criteria; prior premixed
insulin – OAD ¼ all patients who were treated with premixed insulin without OADs prior to the observational study; prior premixed insulin + OAD ¼ all patients
who were treated with premixed insulin plus OADs prior to the observational study. Insulin glargine + OAD set ¼ all patients who were treated with insulin glargine
plus OADs during the observational period. OAD, oral antidiabetic agent; FBG, fasting blood glucose; HbA1c, glycosylated haemoglobin.
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therapy
In the full data set, physicians consistently rated insu-
lin glargine therapy as very good or good for the rated
aspects of therapy (Table 4) – quality of life (94.1%),
BG control (87.6%) and weight management (68.9%).
Only 2.9% of physicians rated the treatment safety of
insulin glargine as satisfactory or unsatisfactory, and
95.9% rated treatment safety with insulin glargine as
good or very good. Physicians also reported that the
demands placed on their time with insulin glargine
were either very good or good (89.7%).
In the full data set, continuation of insulin glar-
gine therapy was planned for 6163 patients (97.7%)
at the end of the observation period. Of the 116
patients who stopped therapy with insulin glargine,
the most common reasons were ‘inadequate BG con-
trol’ (n ¼ 53), ‘change of therapy’ (n ¼ 42), ‘patient
lost to follow-up’ (n ¼ 28) or ‘treatment no longer
considered necessary at the end of observation’
(n ¼ 5). For 29 patients, there was no information
on whether insulin glargine treatment was continued
at the end of the observation period. In the insulin
glargine + OAD set, continuation of insulin glar-
gine plus OAD therapy was planned for 4929
patients (97.7%).
Discussion
Here, we describe a non-interventional, non-rando-
mised observational study that was undertaken to
document postmarketing experience of transferring
patients with T2DM from premixed insulin to insu-
lin glargine. This study demonstrates for the ﬁrst
time in daily clinical practice that initiation of insu-
lin glargine with or without OADs improves glycae-
mic control in patients with T2DM who were poorly
controlled with premixed insulin prior to the obser-
vation period. Signiﬁcant improvements in both
HbA1c and FBG were observed during the 12-week
observation period in patients treated with insulin
glargine with or without OADs. Furthermore, body
weight was reduced over the 12-week observational
period with relatively small increases in daily insulin
dose. The improvements in FBG, HbA1c and
body weight were also observed in the subsets of the
full data population, including the insulin
glargine + OAD set.
The results presented in this observational study
were broadly consistent, irrespective of the patient
subsets, and show that the initiation of insulin glar-
gine in patients previously treated with premixed
insulin was associated with signiﬁcant improvements
Table 3 Preprandial and 2-h postprandial blood glucose and body weight at the start and at the end of the 12-week observation period
Factor
Full data set
(n ¼ 6308)
Prior premixed
insulin – OADs
(n ¼ 3098)
Prior premixed
insulin + OADs
(n ¼ 3210)
Insulin
glargine + OAD
set (n ¼ 5045)
n Mean ± SD n Mean ± SD n Mean ± SD n Mean ± SD
Prandial blood glucose
Preprandial
Start [mmol/l (mg/dl)] 2870 9.7 ± 2.6 (174 ± 46) 1409 9.6 ± 2.4 (173 ± 44) 1461 9.7 ± 2.7 (175 ± 48) 2265 9.6 ± 2.5 (173 ± 45)
End [mmol/l (mg/dl)] 2366 6.8 ± 1.3 (122 ± 23) 1144 6.7 ± 1.2 (121 ± 22) 1222 6.8 ± 1.3 (122 ± 24) 1896 6.8 ± 1.3 (122 ± 23)
2-h postprandial
Start [mmol/l (mg/dl)] 2870 10.8 ± 2.8 (195 ± 50) 1409 10.8 ± 2.8 (195 ± 50) 1461 10.9 ± 2.8 (196 ± 50) 2265 10.9 ± 2.8 (196 ± 50)
End [mmol/l (mg/dl)] 2366 7.8 ± 1.5 (140 ± 27) 1144 7.8 ± 1.4 (140 ± 25) 1222 7.8 ± 1.6 (140 ± 29) 1896 7.8 ± 1.6 (141 ± 28)
Proportion of patients reaching postprandial therapeutic target
Number of patients with valid data 2183 1075 1108 1719
< 7.2 mmol/l (< 130 mg/dl)* 839 38.4 399 37.1 440 39.7 639 37.2
7.2–8.9 mmol/l (130–160 mg/dl)* 966 44.3 493 45.9 473 42.7 763 44.4
Total < 8.9 mmol/l (< 160 mg/dl)* 1805 82.7 892 83.0 913 82.4 1402 81.6
Body weight
Start (kg) 6175 84.8 ± 14.4 3030 84.0 ± 14.2 3145 85.6 ± 14.6 4958 85.2 ± 14.4
End (kg) 6175 83.3 ± 14.1 3030 82.5 ± 14.0 3145 84.0 ± 14.2 4958 83.6 ± 14.1
Change )1.5 ± 3.3 )1.5 ± 3.3 )1.6 ± 3.3 )1.5 ± 3.2
As some patients had incomplete data, the numbers of patients with valid data for each characteristic are given. Reasons for missing data were not collected.
Results are means ± SD; *n, per cent; p £ 0.001 for within-group change in body weight from start of observation. Full data set ¼ all patients who fulﬁlled the
inclusion criteria; prior premixed insulin – OAD ¼ all patients who were treated with premixed insulin without OADs prior to the observational study; Prior premixed
insulin + OAD ¼ all patients who were treated with premixed insulin plus OADs prior to the observational study. Insulin glargine + OAD set ¼ all patients who
were treated with insulin glargine plus OADs during the observational period. SD, standard deviation; OAD, oral antidiabetic agents.
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whether or not patients were previously taking
OADs.
In a recent observational study of 12,216 patients
with T2DM poorly controlled with OADs alone
[HbA1c: 8.7 ± 1.4%; FBG: 11.2 ± 3.1 mmol/l
(202 ± 56 mg/dl)], addition of once-daily insulin
glargine was associated with improvements in FBG
[7.4 ± 1.8 mmol/l (133 ± 33 mg/dl)] and HbA1c
(7.2 ± 0.9%) at 3 months, which were maintained at
9 months (6). In our study, we show that switching
from premixed insulin to insulin glargine is associ-
ated with signiﬁcant improvements in FBG and HbA1c
after only 12 weeks. Furthermore, the majority of
patients achieved the target FBG, HbA1c or PPBG.
Premixed insulin is a common therapy for T2DM
and approximately 40% of patients are treated with
premixed insulin worldwide (1), while a recent Ger-
man study suggested that premixed insulin consti-
tutes the majority (> 80%) of insulin usage in
patients with either T1 or T2DM (7).
In the transition to insulin glargine therapy, OADs
are typically used in combination. In the present
study, some of the patients previously treated with
premixed insulin (with or without oral antidiabetic
agents) switched to insulin glargine, but did not take
Table 4 Physician assessment of insulin glargine therapy
Factor
Full data set
(n ¼ 6308)
Prior premixed
insulin – OADs
(n ¼ 3098)
Prior premixed
insulin + OADs
(n ¼ 3210)
Insulin
glargine + OAD
set (n ¼ 5045)
n % n % n % n %
Quality of life
Very good 2615 41.5 1308 42.2 1307 40.7 2085 41.3
Good 3320 52.6 1626 52.5 1694 52.8 2673 53.0
Satisfactory 277 4.4 118 3.8 159 5.0 221 4.4
Unsatisfactory 19 0.3 7 0.2 12 0.4 15 0.3
No response given 77 1.2 39 1.3 38 1.2 51 1.0
Blood glucose control
Very good 2921 46.3 1479 47.7 1442 44.9 2310 45.8
Good 2606 41.3 1259 40.6 1347 42.0 2103 41.7
Satisfactory 602 9.5 274 8.8 328 10.2 491 9.7
Unsatisfactory 118 1.9 58 1.9 60 1.9 101 2.0
No response given 61 1.0 28 0.9 33 1.0 40 0.8
Weight management
Very good 1691 26.8 863 27.9 828 25.8 1335 26.5
Good 2655 42.1 1335 43.1 1320 41.1 2136 42.3
Satisfactory 1455 23.1 675 21.8 780 24.3 1182 23.4
Unsatisfactory 422 6.7 183 5.9 239 7.5 334 6.6
No response given 85 1.4 42 1.4 43 1.3 58 1.2
Safety
Very good 3426 54.3 1683 54.3 1743 54.3 2765 54.8
Good 2625 41.6 1280 41.3 1345 41.9 2093 41.5
Satisfactory 164 2.6 92 3.0 72 2.2 123 2.4
Unsatisfactory 19 0.3 8 0.3 11 0.3 15 0.3
No response given 74 1.2 35 1.1 39 1.2 49 1.0
Demand on time
Very good 2051 32.5 1036 33.4 1015 31.6 1592 31.6
Good 3608 57.2 1744 56.3 1864 58.1 2959 58.7
Satisfactory 528 8.4 258 8.3 270 8.4 408 8.1
Unsatisfactory 32 0.5 13 0.4 19 0.6 25 0.5
No response given 89 1.4 47 1.5 42 1.3 61 1.2
As some patients had incomplete data the numbers of patients with valid data for each characteristic are given. Reasons for missing data were not collected. Results
are n and per cent. Full data set ¼ all patients who fulﬁlled the inclusion criteria; prior premixed insulin – OAD ¼ all patients who were treated with premixed
insulin without OADs prior to the observational study; prior premixed insulin + OAD ¼ all patients who were treated with premixed insulin plus OADs prior to the
observational study. Insulin glargine + OAD set ¼ all patients who were treated with insulin glargine plus OADs during the observational period. OADs, oral
antidiabetic agents.
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from premixed insulin without or with OADs to
insulin glargine without OADs, improvements in
HbA1c, FBG and PPBG were consistent with the
insulin glargine + OAD and the full data sets (data
not shown).
Weight gain is a seemingly unavoidable occurrence
with initiation of insulin therapy in T2DM (8). In a
28-week study comparing initiation of insulin ther-
apy with either biphasic insulin aspart (70/30) or
insulin glargine, once-daily insulin glargine was asso-
ciated with signiﬁcantly less weight gain compared
with twice-daily biphasic insulin aspart (+3.5 vs.
+5.4 kg; p < 0.01) (9). Furthermore, educational
programmes, if combined with insulin glargine ther-
apy, may help prevent the weight gain otherwise
associated with insulin therapy (10). In this study,
the authors used a programme comprising 90-min
lessons over a 12-week duration, with focus on vari-
ous topics, such as ‘insulin dosing and injection’,
‘BG self-monitoring’, ‘food and diet’, ‘physical exer-
cise’ and ‘diabetic complications’. Patients were
monitored for 30 months and were not to make die-
tary adjustments as part of the study. No weight gain
was seen in the overall study population. In our
study, we show that weight loss can be achieved in
clinical practice (mean weight change: )1.5 ± 3.3 kg;
median: )1.0 kg; interquartile range: )3.0 to 0.0 kg),
and that this occurs in conjunction with the majority
of patients reaching target FBG, HbA1c (74.3% of
patients with HbA1c < 7.5%) or PPBG [82.7% of
patients with PPBG < 8.9 mmol/l (< 160 mg/dl)].
This is in support of a previous observational study
of everyday clinical practice, where insulin glargine
was initiated for 12,216 patients with T2DM previ-
ously inadequately controlled by OAD therapy (6),
where BMI decreased by 0.3 kg/m
2 at 3 months
(n ¼ 10,692), from 29.0 ± 4.7 kg/m
2 at the start of
observation. At the 9-month follow up, mean change
in BMI from the start of observation was )0.5 kg/m
2
(n ¼ 5324), and was greatest ()2.1 kg/m
2) in those
patients who had BMI ‡ 35 kg/m
2 at the start of
observation. The lower dose of external insulin glar-
gine plus the mobilisation of endogenous insulin by
OADs compared with the higher dose of external
premixed insulin at the start of the observation may
be associated with the weight loss observed in our
study.
A further barrier to the initiation of insulin ther-
apy for T2DM is hypoglycaemia (11). In a 24-week
randomised controlled trial (RCT) comparing initia-
tion of basal insulin added to OADs vs. twice-daily
premixed insulin, the majority of patients in both
groups (61.6% vs. 67.2%) experienced at least one
episode of hypoglycaemia, but the prevalence was
signiﬁcantly higher in the premixed insulin group
(4). In our study, only 16 patients reported an epi-
sode of hypoglycaemia, of which 13 were classed as
ADRs. However, this may partly be due to the less
stringent target levels used in everyday clinical prac-
tice compared with the study by Janka et al. (4),
which set target values of HbA1c £ 7.0% and
FBG £ 5.6 mmol/l (£ 100 mg/dl).
In a 28-week RCT comparing insulin glargine with
NPH insulin in patients who were inadequately con-
trolled (HbA1c 7.0–12.0%) with insulin, < 30% of
patients achieved target FBG levels [< 6.7 mmol/l
(< 120 mg/dl)] at the study end (12). The authors
reported that this may have been due to reluctance
of the investigators and/or subjects to intensively
titrate the insulin dose likely because of fear of hypo-
glycaemia or weight gain. In our study, almost 50%
of patients achieved FBG levels of £ 6.7 mmol/l
(£ 120 mg/dl) and > 70% achieved HbA1c levels
of £ 7.5%.
There are limitations of the study that mean care
should be taken when interpreting our results. First,
as this was an observational study and not controlled
by the inclusion of a comparator arm, it is likely that
some of the improvements observed may be related
to a study effect rather than the therapeutic regimen
based on insulin glargine plus OADs. Unfortunately,
as this study was uncontrolled, it is not possible to
delineate between the study effect and the regimen
used. Nevertheless, the improvements in glycaemic
control over the study period are consistent with
RCTs (13,14).
Second, the duration of the observation period
was restricted to 12 weeks; however, subsequent fol-
low ups are planned at 1 year to address longer-term
beneﬁts of insulin glargine plus OADs in clinical
practice, particularly on the overall weight loss and
low incidence of hypoglycaemia observed here.
In the present study, the target HbA1c was £ 7.5%
and was achieved by almost 75% of the patients.
However, the International Diabetes Federation (15)
and the American Diabetes Association (16) have set
target HbA1c levels of £ 6.5% and £ 7.0%, respec-
tively. It is likely that if the target HbA1c had been
set at equivalent levels, a more intensive treatment
algorithm would be needed, which may, however,
increase risk of hypoglycaemia. Thus, the low inci-
dence of hypoglycaemia observed in the present
study may reﬂect the less stringent titration targets
used [i.e. FBG < 6.7 mmol/l (< 120 mg/dl) and
HbA1c < 7.5%]. However, a number of trials have
demonstrated that greater improvements in FBG
and/or HbA1c can be achieved with insulin glargine
vs. NPH insulin, with a lower risk of hypoglycaemia,
even with intensive insulin titration regimens
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reﬂect the self-report methods used, as patients and
physicians were not requested to provide speciﬁc
details of each episode. Thus, the occurrence of hyp-
oglycaemia may have been underreported by patients
in the present study.
In the present study, approximately 75% of
patients met our target HbA1c level of £ 7.5%, with a
mean of 7.2% for the full data set. While this is close
to the ADA target (and undoubtedly, some patients
will have met the ADA, and possibly IDF targets), we
suggest that further intensiﬁcation of therapy, per-
haps by adding one or more bolus insulin injections,
would help improve glycaemic control further (18).
Indeed, the improvements observed in the present
study provide a foundation on which further thera-
pies should be added.
In summary, in this observational study of every-
day clinical practice, we have shown here for the ﬁrst
time that once daily insulin glargine plus OADs is an
effective therapeutic regimen with a good safety pro-
ﬁle for patients with T2DM who were inadequately
controlled with premixed insulin. Furthermore, in a
clinical setting, improvements in glycaemic control
can be achieved with low risk of weight gain and
with a low prevalence of hypoglycaemia in a large
study population (6308 patients). It remains to be
seen whether these improvements are maintained
after a longer duration of time in this cohort
of patients.
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